Dasatinib for HIV-1 Reservoir Reduction

Inclusion Criteria: * HIV-1 infection * Active antiretroviral therapy received continuously for 48 months (or longer) * CD4+ cell count \>450 cells/mm3 obtained within 12 months prior to study entry * Plasma HIV-1 RNA level below the lower limit of quantification within 90 days prior to study entry * Plasma HIV-1 RNA levels below the lower limit of quantification for \>36 months at time of study entry * The following laboratory values obtained within 90 days prior to entry: * Absolute neutrophil count (ANC) above the lower limit of normal * Hemoglobin above the lower limit of normal * Platelet count above the lower limit of normal * Aspartate aminotransferase (AST) (SGOT), alanine aminotransferase (ALT) (SGPT), and alkaline phosphatase \<1.5 x ULN * Total bilirubin \<1.5 x ULN * Negative hepatitis B virus (HBV) surface antigen (HBsAg) * Negative HBV core antibody with one exception: individuals with positive HBV core antibody and HBV surface antibody are eligible for enrollment * Negative hepatitis C virus (HCV) antibody (anti-HCV) or, if the anti-HCV is positive, a negative HCV RNA PCR * Estimated glomerular filtration rate (eGFR) \>70 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) 2021 equation or serum creatinine \<1.2 x ULN * QTc interval \<450 milliseconds on EKG performed at screening visit * Women who are able to become pregnant must have a negative serum or urine pregnancy test at screening and within 48 hours p…